TY - JOUR
T1 - Can analyses of electronic patient records be independently and externally validated? Study 2--the effect of β-adrenoceptor blocker therapy on cancer survival : a retrospective cohort study
AU - Springate, D. A.
AU - Ashcroft, D. M.
AU - Kontopantelis, E.
AU - Doran, T.
AU - Ryan, R.
AU - Reeves, D.
PY - 2015/4/13
Y1 - 2015/4/13
N2 - OBJECTIVES:
To conduct a fully independent, external validation of a research study based on one electronic health record database using a different database sampling from the same population.
DESIGN:
Retrospective cohort analysis of β-blocker therapy and all-cause mortality in patients with cancer.
SETTING:
Two UK national primary care databases (PCDs): the Clinical Practice Research Datalink (CPRD) and Doctors' Independent Network (DIN).
PARTICIPANTS:
CPRD data for 11,302 patients with cancer compared with published results from DIN for 3462 patients; study period January 1997 to December 2006.
PRIMARY AND SECONDARY OUTCOME MEASURES:
All-cause mortality: overall; by treatment subgroup (β-blockers only, β-blockers plus other blood pressure lowering medicines (BPLM), other BPLMs only); and by cancer site.
RESULTS:
Using CPRD, β-blocker use was not associated with mortality (HR=1.03, 95% CI 0.93 to 1.14, vs patients prescribed other BPLMs only), but DIN β-blocker users had significantly higher mortality (HR=1.18, 95% CI 1.04 to 1.33). However, these HRs were not statistically different (p=0.063), but did differ for patients on β-blockers alone (CPRD=0.94, 95% CI 0.82 to 1.07; DIN=1.37, 95% CI 1.16 to 1.61; p<0.001). Results for individual cancer sites differed by study, but only significantly for prostate and pancreas cancers. Results were robust under sensitivity analyses, but we could not be certain that mortality was identically defined in both databases.
CONCLUSIONS:
We found a complex pattern of similarities and differences between databases. Overall treatment effect estimates were not statistically different, adding to a growing body of evidence that different UK PCDs produce comparable effect estimates. However, individually the two studies lead to different conclusions regarding the safety of β-blockers and some subgroup effects differed significantly. Single studies using even internally well-validated databases do not guarantee generalisable results, especially for subgroups, and confirmatory studies using at least one other independent data source are strongly recommended.
AB - OBJECTIVES:
To conduct a fully independent, external validation of a research study based on one electronic health record database using a different database sampling from the same population.
DESIGN:
Retrospective cohort analysis of β-blocker therapy and all-cause mortality in patients with cancer.
SETTING:
Two UK national primary care databases (PCDs): the Clinical Practice Research Datalink (CPRD) and Doctors' Independent Network (DIN).
PARTICIPANTS:
CPRD data for 11,302 patients with cancer compared with published results from DIN for 3462 patients; study period January 1997 to December 2006.
PRIMARY AND SECONDARY OUTCOME MEASURES:
All-cause mortality: overall; by treatment subgroup (β-blockers only, β-blockers plus other blood pressure lowering medicines (BPLM), other BPLMs only); and by cancer site.
RESULTS:
Using CPRD, β-blocker use was not associated with mortality (HR=1.03, 95% CI 0.93 to 1.14, vs patients prescribed other BPLMs only), but DIN β-blocker users had significantly higher mortality (HR=1.18, 95% CI 1.04 to 1.33). However, these HRs were not statistically different (p=0.063), but did differ for patients on β-blockers alone (CPRD=0.94, 95% CI 0.82 to 1.07; DIN=1.37, 95% CI 1.16 to 1.61; p<0.001). Results for individual cancer sites differed by study, but only significantly for prostate and pancreas cancers. Results were robust under sensitivity analyses, but we could not be certain that mortality was identically defined in both databases.
CONCLUSIONS:
We found a complex pattern of similarities and differences between databases. Overall treatment effect estimates were not statistically different, adding to a growing body of evidence that different UK PCDs produce comparable effect estimates. However, individually the two studies lead to different conclusions regarding the safety of β-blockers and some subgroup effects differed significantly. Single studies using even internally well-validated databases do not guarantee generalisable results, especially for subgroups, and confirmatory studies using at least one other independent data source are strongly recommended.
KW - Oncology
KW - Primary care
KW - STATISTICS & RESEARCH METHODS
U2 - 10.1136/bmjopen-2014-007299
DO - 10.1136/bmjopen-2014-007299
M3 - Article
C2 - 25869690
SN - 2044-6055
VL - 5
JO - BMJ open
JF - BMJ open
IS - 4
M1 - e007299
ER -
